Basic Company Data Data as of: February 10, 2011 Current Price $86.

98
Symbol ALXN ALEXION PHARMACEUTICALS INC H&C Composite Score
Description Alexion Pharmaceuticals, Inc., a biopharmaceutical company, researches and
Strong Buy
develops proprietary immunoregulatory compounds for the treatment of autoimmune
and cardiovascular diseases. The Company develops C5 complement inhibitors and
Apogens which are two classes of potential therapeutic compounds designed to
8.9
selectively target specific disease-causing segments of the immune system.

Sector Health Care

Industry Pharmaceuticals, Biotechnology 0 1 2 3 4 5
Last Report Date 2/10/2011 Technical Score Fundamental Score
Earnings Date 2/10/2011 IPO Date 2/27/1996
Fundamentals Technicals
Market Cap. $7.9 B BETA 0.82 Price $86.98 MACD Overbought
Price/Earnings 82.84 1Yr. EPS Growth Rate % 13.40% 50-Day MA $81.69 Stochastics Trend Down
Forward Price/Earnings 28.53 5Yr. Avg. EPS Growth Rate % #N/A N/A 200-Day MA $64.61 RSI Signal Trend Up
Price/Book 9.11 EPS Growth QoQ 21.74% 50/200 Day MA $17.08 S/T Trend Up
Forward PEG Ratio #N/A N/A Revenue Growth QoQ 40.96% Volume Pressure 1.14 L/T Trend Up
Return on Equity 20.70 Dividend Yield 0.00% Average Daily Volume 571,606 Bull / Bear Bull Trend
LT Debt/Equity 0.43% Cash Flow Per Share 1.33 M-Score (0 - 100%) 92%
H&C Fundamental Score 4.3 H&C Technical Score 4.6
Ownership Data
Inst. Buy/Sell Ratio 2.20 Management Ownership 1.70% 50 Day Moving Average S/T Support L/T Support
% Change of Insider Holdings 0.67% Short Interest Ratio 5.54 20 Day Moving Average S/T Resistance L/T Resistance

ALEXION PHARMACEUTICALS INC $90

$88
$86
$84
$82
$80
$78
$76
$74
$72
$70
$68
$66
$64
$62

10.0
Bull Trend Bear Trend

5.0

0.0
3.0
Up / Down Volume Ratio 2.5
2.0
1.5
1.0
0.5
0.0
60

40

20

0
18-Oct-10 1-Nov-10 15-Nov-10 30-Nov-10 14-Dec-10 29-Dec-10 12-Jan-11 27-Jan-11 10-Feb-11
Volume x100,000
Fundamentals
ALEXION PHARMACEUTICALS INC
1
Earnings Per Share 2
Reported Estimate Target Price 19 Reported Estimate
$0.70 $100
$0.60 $90
$0.50 $80
$0.40 $70
$0.30 $60
$0.20 $50

$0.10 $40

$0.00 $30

-$0.10 $20

-$0.20 $10

-$0.30 $0

Total Revenues 1
Reported Estimate
Ownership EPS & Revenue Growth
Investment Advisor 84.79% Quarter EPS Growth Rev. Growth
$250
Hedge Fund Manager 7.89% FQ1 2009 191% # 78%
Pension Fund (ERISA) 2.31% FQ2 2009 667% 55%
Mutual Fund Manager 1.72% FQ3 2009 26% 34%
$200
Individual 1.64% FQ4 2009 35% 43%
Insurance Company 1.00% FQ1 2010 44% 45%
$150
Corporation 0.39% FQ2 2010 4% 36%
Bank 0.13% FQ3 2010 3% 38%
FQ4 2010 22% 41%
$100 Top Holders and % Outstanding Forward Growth Estimates
FIDELITY MANAGEMENT 14.93% Quarter EPS Growth Rev. Growth
T ROWE PRICE ASSOCIA 6.76% FQ1 2011 133% 39%
$50
COLUMBIA WANGER ASSE 4.74% FQ2 2011 135% 38%
VANGUARD GROUP INC 3.72% FQ3 2011 100% 30%
WELLS CAPITAL MANAGE 3.41% FQ4 2011 120% 26%
$0
JP MORGAN CHASE & CO 3.16%
WESTFIELD CAPITAL MG 2.63%
AMERICAN CENTURY COM 2.49%

Largest Geographic Segmentation of Revenue Product Segmentation of Revenue

Yearly Yearly
Segment Name FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 Segment Name FY 2009 FY 2008 FY 2007 FY 2006 FY 2005
Outside U.S. 226.97 145.80 20.19 #N/A N/A #N/A N/A Soliris $386.80 $259.00 $66.38 #N/A N/A #N/A N/A
United States 159.83 113.20 51.86 1.56 1.06 Contract Research Revenue #N/A N/A $0.10 $5.66 $1.56 $1.06
Worldwide (Contract Research) #N/A N/A 0.10 5.66 #N/A N/A #N/A N/A

Disclosure: This material is provided for information only and is not intended as a recommendation or an offer or solicitation for the purchase or sale of any security or financial instrument. This material is not a complete analysis of all material facts respecting any issuer, industry or
security or of your investment objectives, parameters, needs or financial situation, and therefore is not a sufficient basis alone on which to base an investment decision. Horowitz & Company clients may hold positions (long or short) in investments discussed. Please click for detailed
disclosures and additional information about our stock ratings and scoring.

2/10/2011